Publisher's Synopsis
Trials for acute stroke are becoming more and more necessary with the emergence of new drug therapies. However, many critical issues still have to be resolved, including numerous methodological and ethical problems. This text examines these difficulties, in particular the lack of co-ordination among those involved in acute drug trials, including investigators, committees and sponsors. It also highlights the wide variations that exist between standard treatments in various stroke centres.
